Adults with chronic hepatitis C virus genotype 1 infection with viremia levels <6 million IU/mL who were treatment-naive and noncirrhotic might be successfully treated for 8 weeks with sofosbuvir/ledipasvir. For this pilot study, researchers wanted a prospective, open-label, multicenter trial to assess the effectiveness and safety of this reduced treatment term in adolescents (aged 12). The effectiveness criterion was persistent virological response 12 weeks after therapy ended. Adverse occurrences and clinical/laboratory data were used to assess safety. Fourteen vertically infected teenagers (median age 16.5 years, Q1 14.1–Q3 17.4; female 57.1%) were recruited and treated (June 2018–January 2019). Overall, the end-of-treatment response and sustained virological response 12 weeks later were both 100%. There were no grade 3 to 4 adverse events or major adverse events recorded.
Reference:journals.lww.com/jpgn/Fulltext/2019/11000/Shortened_8_Week_Course_of_Sofosbuvir_Ledipasvir.17.aspx
